Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001641172-25-011229
Filing Date
2025-05-16
Accepted
2025-05-16 15:38:26
Documents
22

Document Format Files

Seq Description Document Type Size
1 DEFR14A formdefr14a.htm   iXBRL DEFR14A 510512
2 GRAPHIC formdef14a_001.jpg GRAPHIC 9727
3 GRAPHIC formdef14a_002.jpg GRAPHIC 2631
4 GRAPHIC formdef14a_003.jpg GRAPHIC 2629
5 GRAPHIC formdef14a_004.jpg GRAPHIC 2533
6 GRAPHIC formdef14a_005.jpg GRAPHIC 3302
7 GRAPHIC proxy_001.jpg GRAPHIC 349708
8 GRAPHIC proxy_002.jpg GRAPHIC 247234
  Complete submission text file 0001641172-25-011229.txt   2416680

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE kapa-20241231.xsd EX-101.SCH 3429
10 XBRL DEFINITION FILE kapa-20241231_def.xml EX-101.DEF 5352
11 XBRL LABEL FILE kapa-20241231_lab.xml EX-101.LAB 53094
12 XBRL PRESENTATION FILE kapa-20241231_pre.xml EX-101.PRE 41489
24 EXTRACTED XBRL INSTANCE DOCUMENT formdefr14a_htm.xml XML 3347
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-42275 | Film No.: 25958709
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)